Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Richter transformation: Results from the ongoing phase 1 CaDAnCe-101 study

View Full Paper
Ask AI
Bookmark
Share

Authors

MTMeghan C. ThompsonMDMartin DreylingIAInhye E. Ahn

Discussion

Loading...

Member takes

Overview

Preliminary results demonstrate BGB-16673's efficacy with an overall response rate of 52.4% in patients with relapsed/refractory Richter transformation, suggesting a new treatment avenue.

Key Points

  • BGB-16673 achieved an overall response rate of 52.4% in patients with relapsed/refractory Richter transformation.
  • Median follow-up for participants was 5.2 months, with responses lasting over 6 months in some cases.
  • Safety analysis revealed that 91.7% of patients experienced treatment-emergent adverse events, but the overall profile remained tolerable.
  • The maximum tolerated dose is still being defined in ongoing phase 1 portions of the study evaluating BGB-16673.

Cite This Study

Thompson et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e20ehttps://doi.org/10.1182/blood-2025-3895
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory indolent non-Hodgkin lymphoma from the ongoing phase 1 CaDAnCe-101 study2025
  2. 2CaDAnCe-304, a phase 3, open-label, randomized study to evaluate the safety and efficacy of Bruton tyrosine kinase degrader BGB-16673 compared with pirtobrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma2025 · 1 citations
  3. 3CaDAnCe-104, an ongoing, open-label, phase 1b/2 master protocol study of Bruton tyrosine kinase degrader BGB-16673 in combination with other agents in patients with relapsed/refractory B-cell malignancies2025 · 2 citations
  4. 4Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Waldenström macroglobulinemia from the ongoing phase 1 CaDAnCe-101 study2025 · 2 citations
  5. 5CaDAnCe-302, a phase 3, open-label, randomized study of BGB-16673 compared with idelalisib + rituximab (R), bendamustine + R, or venetoclax + R re-treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma previously exposed to both a BTK and BCL2 inhibitor2025